Global stock

LSEGBP

GSK plc

GSK.L

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

63/ 100

Overall score·GSK.L

Current price

18.94GBP

23/10/2026

P/E, P/B

Valuation

Neutral

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Forward P/E kolem 10 a EV/EBITDA 8,4 ukazují na relativně příznivé ocenění, zatímco vysoký PEG a mimořádně vysoké P/B jsou varovnými ukazateli; P/B může být zkreslené nízkou účetní hodnotou vlastního kapitálu. Silné marže a nízká beta vyvažují pokles EPS o 69,5 % a zvýšené zadlužení, přičemž tržby rostou mírně.

§ Outlook vs S&P 500Next 12 months

Probably yes

Estimated chance of beating the index: about 61%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Metrics summary

A quick look at GSK plc (GSK.L) combining financial health, the short-term signal, valuation, DCF, management quality and operating metrics. It is analytical context, not a recommendation to buy or sell.

63/100

The overall score is based mainly on long-term fundamentals, complemented by the current signal and the available qualitative rating of the company.

74/100

Strongly positive signal based on current news, price action and the economy.

55/100

A lower score means the stock is expensive relative to the company's earnings and assets.

16% below fair value

An estimate of what the stock should be worth based on the company's future cash.

+5%

How fast the company's revenue grows year on year.

78/100

How much the company earns from each unit of revenue and from invested capital.

58/100

Debt level, share-price volatility and how resilient the company is in bad times.

72/100

AI estimate of management quality, execution and capital allocation.

82/100

AI estimate of the company's durable competitive advantage.

§ Context and events

Management

Luke Victor Miels je CEO a ředitel společnosti; Julie Belita Brown zastává funkci CFO a výkonné ředitelky. Strategie se zaměřuje na vakcíny a specializovaná léčiva, rozvoj výzkumného portfolia a digitálních schopností. Shobie Ramakrishnan vede digitální a technologickou oblast.

Articles about GSK plc, in Czech (1)

GSK spouští nabídku na převzetí Nuvalent za 124 USD za akcii

GSK plc oznámila zahájení výběrové nabídky na akcie Nuvalent, přičemž nabízí 124 USD za akcii. Tato akvizice má posílit její pozici v oblasti výzkumu a vývoje léčiv pro onkologii a vzácné nemoci.

7 July 2026· 2 min

§ Upcoming results

28 October 2026

Tomorrow

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is GSK plc (GSK.L)?

GSK plc (GSK.L) is a global stock traded on LSE. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the GSK plc price today?

As of 23 October 2026, GSK plc trades at about 18.94 GBP per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy GSK plc?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does GSK plc pay a dividend?

GSK plc either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is GSK plc a good investment in 2026?

Our AI signal currently rates GSK plc as strongly positive (score 74/100). Financial health comes out at 63/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. The DCF model currently puts the price about 16 % below its model fair value. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy GSK plc

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Strongly positive

Earnings tomorrow

On 28 October 2026 the company publishes its quarterly results. This period tends to bring large price moves — the signal below does not reflect the results yet.

News summary

No newer news

Signal 29/09, 12:30

IBM/AI dopady a novinky kolem AI v segmentu zdravotnické farmacie a technologií mohou tlumit volatilitu; klíčové dökazy jsou posílení AI/Cloud partnerství a posun v segmentu zdravotnických řešení.

Náznaky pozitivního trendu z posílení AI ekosystému (např. Shopify+Meta AI, Microsoft Azure/M365 s výhledem na FY2027) a rozšiřující dohody o LNG/energetických projektech ukazují širší pozitivní sentiment v technologickém a energetickém průmyslu. Technicky je momentum nad 50, Trend roste, RSI nad 50 podporuje krátkodobý náhled. Pohyb cen v 7–30 dnech ukazuje stabilní mírný vzestup.

Risks: Krátkodobý sentiment může být ovlivněn rychlými změnami v AI alokaci a regulačním prostředím; slabší makro data nebo zhoršení vyhlídek v segmentu zdravotnických technologií by mohlo otočit trend. Zatížení volatilitou může snížit jistotu krátkodobého průlomu.

More about the signal

Ask the AI

§ Model fair value (DCF)

Fairly valued16% below fair value

22.56

range 17.7 – 29.6

Current price

18.94 GBP

23 Oct 26

PriceFair value range (DCF)UndervaluedOvervalued

What the calculation is based on

Model

22.56 GBP

range 17.7 GBP – 29.6 GBP

: 5.0%
: 8.5%
: 1.19 GBP

Růst FCF 5 % p.a. představuje umírněný předpoklad pro zavedenou farmaceutickou společnost a zohledňuje růst tržeb, ale i výrazný pokles EPS. Diskontní sazba 8,5 % reflektuje stabilnější profil firmy i nejistotu spojenou s vývojem hospodaření a zadlužením.

DCF terms explained+

DCF (discounted cash flow) estimates how much cash the company will generate in the future and converts it into today's value per share.

Free cash flow (FCF) is the money left after running the business and investing. “12 m” means the last 12 months.

The discount rate expresses risk: the riskier the company, the higher the rate and the lower the fair value.

Fair value is a model estimate — not the market price and not an investment recommendation.

With Premium you can adjust growth, the discount rate and free cash flow, and the fair value recalculates live.

Adjust assumptions14 days free →

A model estimate, not an investment recommendation. Past performance does not guarantee future results.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 18 of 18

Valuation score

4/ 6

6/6 tests available

1. Below DCF fair value

16.0% below the DCF midpoint.

2. Well below DCF value

Discount = below the range or at least 15% below the midpoint.

3. Price vs. the last year

54% above the 1-year low (17.36 GBP to 20.29 GBP), based on stored daily prices.

4. P/E vs. similar companies

P/E 15.8 vs. median 26.7 (71 companies).

5. P/E relative to growth

PEG 6.2; a lower value means cheaper growth.

6. Analyst price target

14.8% vs. the current price, 21 analysts.

Price vs DCF

Current price

18.94 GBP

Low 17.73 GBPHigh 29.58 GBP

Current priceDCF midpoint: 22.56 GBP

Price vs analyst target

Current price

18.94 GBP

Low 14.55 GBPHigh 30.10 GBP

Current priceAverage: 21.75 GBP

DCF gap

within range

The price is within the model range of 17.73 GBP to 29.58 GBP.

Analyst target

+14.8%

Average target 21.75 GBP vs. price 18.94 GBP.

Analyst consensus

Target range

14.55 GBP - 30.10 GBP

Coverage

21 analysts

Analyst consensus

2.5 / 5

Changes 180 d

+0 / -0

EPS next year

6.0%

Revenue next year

4.7%

Valuation multiples

15.8

10.0

430.1

2.3

8.4

6.2

52-week range54% above the low

17.36 GBP20.29 GBP

-70.0%

5.0%

14.5%

33.4%

Price vs 50D2.6%

Price vs 200D-3.1%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 23/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

strong

Vedení získává body za strategické posilování portfolia a nízké uvedené governance riziko, přestože dostupné údaje o dlouhodobé exekuci jsou omezené.

strong

GSK těží z rozsáhlého portfolia vakcín a léčiv, výzkumných kapacit a zavedené globální distribuce, které podporují bariéry vstupu a loajalitu zákazníků.

Information

Type: Global stock
Symbol: GSK.L
Exchange: LSE
Currency: GBP
Sector: Healthcare
: 15.8x
: 75.9B USD
: 106.5 %
: 0.28

§ Risk profile

Výsledky mohou ovlivnit neúspěšné klinické studie, regulatorní rozhodnutí, vypršení patentové ochrany a tlak na ceny léčiv. Pro českého investora navíc kolísání libry vůči koruně mění korunovou hodnotu investice i dividend.

Ask the AI about GSK plc All signals